This article was originally published here
J Cardiol invasive. May 19, 2022: JIC20220519-3. Online ahead of print.
BACKGROUND: Percutaneous balloon aortic valvuloplasty (BAV) is actually recommended as a gateway to surgery or transcatheter aortic valve replacement in patients with severe aortic stenosis (AS) in particular clinical settings. In this pilot study, for the first time, we report our experience of using a non-occlusive balloon for BAV, which does not require rapid ventricular pacing (RVP), in symptomatic high-risk elderly patients with severe AS. .
Methods and Results: From 2018 to 2020, a total of 30 high-risk elderly patients with heart failure due to severe AS were treated with BAV and all were prospectively included in the study. We used infusion balloon valvuloplasty without PVR (True Flow; BD/Bard). Hemodynamic parameters were assessed invasively during catheterization, before and immediately after BAV. All patients were followed regularly to detect the mortality rate. The patients were 87.56 ± 4.10 years old and 23% were men. In the catheterization laboratory, the peak pressure gradient from the left ventricle to the aorta was significantly decreased by 55 mm Hg (interquartile range [IQR], 48.75-66.25) at 26 mm Hg (IQR, 15.7-30) immediately after balloon inflation (P
CONCLUSION: This single-center pilot study represents the first evidence that infusion balloon valvuloplasty without PVR is a safe, valid, and durable option in high-risk, symptomatic elderly patients with severe AS.